Table 2.
Correlation of clinicopathological parameters with BI-RADS classification and peripheral PD-1 expression in breast cancer patients
| Parameter | BI-RADS
|
PD-1
|
||||
|---|---|---|---|---|---|---|
| 3-4B | 4C-6 | P-value | <3.62 | ≥3.62 | P-value | |
| Age, years (mean ± standard) | 50 ± 11 | 53 ± 12 | 0.634 | 51 ± 11 | 53 ± 14 | 0.463 |
| Tumor grade | ||||||
| Grade 1–2 | 21 | 56 | 0.392 | 19 | 59 | 0.754 |
| Grade 3 | 7 | 11 | 3 | 14 | ||
| AJCC stage (n) | ||||||
| I | 12 | 13 | 0.004 | 4 | 21 | 0.778 |
| II–IV | 16 | 72 | 18 | 70 | ||
| Tumor size (n) | ||||||
| T1 | 16 | 19 | 0.001 | 6 | 29 | 0.800 |
| T2–3 | 12 | 66 | 16 | 62 | ||
| Lymph node status (n) | ||||||
| N0 | 17 | 48 | 0.826 | 15 | 50 | 0.338 |
| N1–3 | 11 | 37 | 7 | 41 | ||
| HER-2 status (n) | ||||||
| + | 2 | 31 | 0.003 | 9 | 22 | 0.181 |
| − | 26 | 54 | 13 | 69 | ||
| ER status (n) | ||||||
| + | 22 | 63 | 0.802 | 13 | 72 | 0.060 |
| − | 6 | 22 | 9 | 19 | ||
| PR status (n) | ||||||
| + | 19 | 58 | 0.970 | 8 | 69 | <0.001 |
| − | 9 | 27 | 15 | 22 | ||
Note: Bold values represent statistical significance, P<0.05.
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; PD-1, programmed death 1; AJCC, American Joint Committee on Cancer; n, number of patients; HER-2, human epidermal growth factor receptor-2; ER, estrogen receptor; PR, progesterone receptor.